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Background: Praziquantel is the drug of choice in preventive chemotherapy targeting schistosomiasis. Increasing
large-scale administration of praziquantel requires monitoring of drug efficacy to detect early signs of development
of resistance. Standard protocols for drug efficacy monitoring are necessary. Here, we determined the optimal time
point for praziquantel efficacy assessment against Schistosoma haematobium and studied the dynamics of infection
parameters following treatment.
Methods: Ninety school-aged children from south Côte d’Ivoire with a parasitologically confirmed S. haematobium
infection were treated with a single oral dose of praziquantel (40 mg/kg) and followed up for 62 days post-
treatment. Urine samples were collected on 23 schooldays during this period and were subjected to visual
examination (macrohaematuria), urine filtration and microscopy (S. haematobium eggs) and reagent strip testing
(microhaematuria, proteinuria and leukocyturia).
Results: Observed cure and egg reduction rates were highly dependent on the time point post-treatment. Egg
reduction rates were high (>97%) in weeks 3–9 post-treatment. Cure rates were highest in weeks 6 (92.9%) and 9
(95.0%) post-treatment. The prevalence of infection-associated parameters decreased after treatment, reaching a
minimum of 2.4% in weeks 5 (proteinuria) and 7 (leukocyturia) post-treatment, and 16.3% at the end of week 8
(microhaematuria). Macrohaematuria disappeared between weeks 3 and 6 post-treatment.
Conclusions: For monitoring praziquantel efficacy against S. haematobium, we recommend that the cure rate is
assessed at week 6 post-treatment. The egg reduction rate can be evaluated earlier, from day 14 post-treatment
onwards. Reagent strips are a useful additional tool for evaluating treatment outcomes in areas with high
endemicity, preferably at weeks 5 and 6 post-treatment. The delayed decrease of microhaematuria confirms that
lesions in the urinary tract persist longer than egg excretion post-treatment.
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Schistosomiasis is caused by blood flukes of the genus
Schistosoma. More than 200 million people are infected
worldwide [1]. The largest proportion of infected people
(>90%), live in sub-Saharan Africa, where schistosomiasis is
considered a major public health problem [2-4]. Neverthe-
less, schistosomiasis is often given only token attention,
similar to many other neglected tropical diseases [5-8].
Schistosomiasis is characterized by chronic inflammation
around schistosome eggs that are trapped in host tissues. In
the human host, Schistosoma haematobium is found in the
veins of the small pelvis, causing urogenital schistosomiasis.
Eggs of S. haematobium are usually excreted through the
urinary tract. Typical signs of urogenital schistosomiasis are
macro- and microhaematuria, proteinuria and leukocyturia
[9,10]. School-aged children are at highest risk of infection
and prevalence peaks between the ages of 8 and 15 years
[9,11]. Chronic schistosomiasis is associated with anaemia,
growth stunting and reduced physical fitness [12,13].
The most widely used diagnosis for S. haematobium is
based on the microscopic detection of eggs in urine, using
the filtration method [14,15]. Visual examination of urine
samples for macrohaematuria, urine-albumin and haemo-
globin level assessment with a photometer, and reagent
strip testing for microhaematuria, proteinuria and leukocy-
turia can be used as indirect screening methods for uro-
genital schistosomiasis in areas with high endemicity
[1,9,10,15-18].
The drug of choice for the treatment of schistosomiasis
is praziquantel [9,19-21]. Praziquantel acts against all
schistosome species and has a good safety profile [19-21].
The major shortcoming of praziquantel is its lack of effi-
cacy against schistosomula, the young developing stages of
the parasite [22,23]. There are currently no alternative
treatment options to praziquantel, even though some sub-
stances have shown promising antischistosomal activity
[15,20,24,25]. The global strategy for schistosomiasis con-
trol is preventive chemotherapy, where school-aged chil-
dren (and other high-risk communities) are treated with a
single oral dose of praziquantel (40 mg/kg) without prior
individual diagnosis [6,15,26,27]. This strategy is going to
scale; in 2010, for example, 33.5 million people were trea-
ted with praziquantel [28]. The large-scale administration
of praziquantel without any backup drugs is of a consider-
able concern, should resistance to praziquantel emerge
[21]. Hence, the efficacy of praziquantel against schisto-
somiasis needs careful monitoring [24].
To be able to promptly detect the emergence of resist-
ance in schistosomes, standard protocols for drug efficacy
monitoring are needed [29]. This includes the optimal time
point post-treatment for measuring drug efficacy of prazi-
quantel in urogenital schistosomiasis. Hence, we designed a
study and assessed the dynamics of S. haematobium egg
output over a period of 62 days after administration of asingle dose of praziquantel in school-aged children. Add-
itionally, we studied the post-treatment dynamics of
infection-associated parameters, namely macro- and micro-
haematuria, proteinuria and leukocyturia.
Methods
Study area and population
The study was conducted between March and June 2010 in
a primary school in the village of Grand Moutcho, located
in the district of Agboville (geographical coordinates:
05°56'0'' N latitude and 04°13'0'' W longitude), approxi-
mately 75 km north of Abidjan, in southern Côte d’Ivoire.
The climate in the area is tropical with two rainy seasons
lasting from April to July and from mid-September to
November. The study site was selected based on previous
work conducted in Grand Moutcho that had shown a high
endemicity of S. haematobium [30,31]. All children attend-
ing grades 3, 4, 5 and 6 in the primary school Grand
Moutcho I were invited to participate. Prior to the current
study, the village of Grand Moutcho had not been targeted
by preventive chemotherapy with praziquantel against
schistosomiasis.
Ethical consideration and consent
The study protocol was approved by the institutional re-
search commission of the Swiss Tropical and Public Health
Institute (Basel, Switzerland) and received ethical clearance
from the ethics commission in Basel (EKBB; reference no.
378/09), the ethics commission of the Albert-Ludwigs-
University (Freiburg, Germany; reference no. 06/10), and
the Comité National d’Ethique et de la Recherche (CNER)
in Côte d’Ivoire (reference no. 1993 MSHP/CNER).
District health and education authorities, village leaders,
teachers, children and parents/guardians were informed
about the purpose, procedures and potential risk and ben-
efits of the study and invited to approve their children’s
participation in our study. A written informed consent
was signed by a parent or guardian of eligible children at
the beginning of the study. Children could withdraw from
the study at any time without further obligation. All study
medication was provided free of charge and administered
by qualified medical personnel. At the end of the study, all
children at the school were treated with a single oral dose
of praziquantel (40 mg/kg using a dose pole) and albenda-
zole (400 mg) [26,27].
Sample size
The current study was planned to include approximately
100 school-aged children with a parasitologically con-
firmed S. haematobium infection for monitoring the post-
treatment dynamics of S. haematobium egg output. This
number was partially based on operational consideration
(diagnostic work-up of urine samples at the individual col-
lection days) to ascertain high quality results with the
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enough to study trends over time and to have only a small
impact of single individuals on the overall outcomes.
Study design and procedures
After approval of the study by district authorities, village
leaders and the school director, the teachers were asked to
prepare lists of the children attending their classes. To ob-
tain our desired number of 100 S. haematobium-infected
children, all children registered in grades 3–6 were invited
to participate in the study. Parents/guardians were
informed about the study procedures and questions arising
were discussed in an open forum. Children who provided a
written informed consent signed by their parent/guardian
were eligible to participate in the baseline cross-sectional
screening conducted in March 2010.
At the baseline cross-sectional survey, two urine samples
were collected from each child over consecutive school
days. Children were given 120 ml plastic containers during
the morning break at 10:00 hours and asked to fill the
container with their own urine. Samples were collected
between 10:00 and 14:00 hours, labelled with unique iden-
tifiers and transferred to a field laboratory in Agboville
town. Urine samples were worked up in the afternoon.
First they were visually examined for the presence of blood
(macrohaematuria), and then tested with reagent strips for
microhaematuria, proteinuria and leukocyturia (Combur-7-
TestW, Roche Diagnostics; Basel, Switzerland). Microhae-
maturia was detected above 5 erythrocytes/μl, proteinuria
above 30 mg/dl and leukocyturia above 10 cells/μl. Next,
urine samples were examined with the urine filtration
method for the presence of S. haematobium eggs [14]. In
brief, urine samples were vigorously shaken, and 10 ml
of each sample were pressed through a 13-mm dia-
meter small-meshed filter (20 μm) (Sefar AG; Heiden,
Switzerland). Each filter was placed on a microscope slide
labelled with the child’s identifier, and a drop of Lugol’s
iodine solution was added before examination of the slide
under a microscope by an experienced laboratory techni-
cian. The presence and number of S. haematobium eggs
on each filter was recorded. For quality control, 10% of the
slides were re-examined by a senior laboratory technician.
Children who had at least one S. haematobium egg on
one of the two baseline survey days were invited for treat-
ment and to participate in the follow-up surveys. Children
infected with S. haematobium were treated with a single
oral dose of praziquantel (40 mg/kg). Those children who
were not present on the first day of treatment were treated
on a second treatment day, scheduled 5 days later. After
drug administration children were followed-up over a
period of 62 days. For this purpose, urine samples were al-
ways collected between 10:00 and 14:00 hours on 23 occa-
sions. In the first two weeks we aimed to collect urine
samples from each child on all school days (4 times aweek). In the subsequent six weeks, we aimed to receive
two samples per child per week. In the last week of the
follow-up survey (week 9 post-treatment) only one sample
was collected. The maximum number of times urine sam-
ples were collected per child during each follow-up week
is shown in Figure 1.
As in the baseline survey, on each sampling day, urine
samples were transferred to the laboratory and examined
visually for the presence of macrohaematuria, tested
with reagent strips and subjected to a urine filtration
method for S. haematobium egg detection.
Statistical analysis
Data were double entered in Microsoft Excel, checked for
consistency and analysed in STATA version 10.0
(StataCorp; College Station, USA). The S. haematobium in-
fection prevalence, defined as the percentage of children
with S. haematobium eggs in urine, was calculated at base-
line and at follow-up (on a daily or weekly basis). Whenever
more than one urine sample was examined for a single
child (i.e. at baseline and the weekly follow-up summary), a
child was considered S. haematobium-positive if at least
one egg was detected in at least one of the urine samples
submitted in a specific week.
S. haematobium eggs counted on a filter are expressed as
number of eggs/10 ml of urine. If a urine sample contained
less than 10 ml, the egg count was adjusted to 10 ml. To as-
sess the infection intensity before and on a weekly basis
after treatment, the available egg count records per child
were averaged. The S. haematobium infection intensity was
classified into light (<50 eggs/10 ml of urine) and heavy
(≥50 eggs/10 ml of urine), as defined by the World Health
Organization (WHO) [26].
The group egg output intensity before and on a daily and
weekly basis after treatment was determined by calculating
the group’s geometric mean (GM; formula: GM (egg count
+1) – 1) and arithmetic mean (AM) egg count values, in-
cluding all available individual averaged egg counts.
Since praziquantel treatment was administered on two
different days, daily follow-up results are presented for each
of the two treatment groups separately. Weekly prevalence
rates and AM and GM egg count values include combined
data from both treatment groups.
For drug efficacy assessment, cure rate (CR; formula:
[number of children excreting no S. haematobium eggs
/ number of children with confirmed infection before
treatment] x 100) and egg reduction rate (ERR; formula
AM: 1 – [AM egg count post-treatment / AM egg counts
pre-treatment] x 100); formula GM: 1 – [GM egg count
post-treatment / GM egg counts pre-treatment] x 100)
were calculated for each time point post-treatment. Most
former studies used GM as standard for determining ERR
[29], but discussions are underway whether AM should be
used instead. Hence, we present both approaches to
Figure 1 Timeline of a study assessing the dynamics of S. haematobium egg output and associated infection parameters after
praziquantel treatment, among school-aged children in south Côte d’Ivoire in 2010. Flow chart showing the number of children invited to
participate in the study, the children included in the baseline screening, and finally the overall compliance of children participating in the 62-day
longitudinal surveillance to measure the dynamics of S. haematobium egg output and associated infection parameters after a single oral dose of
praziquantel (40 mg/kg). The timeline shows the frequency of urine sampling (yellow bars) during the follow-up survey with the maximum
number of urine samples collected per child during each follow-up week after treatment.
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and potential future studies.
Additionally, the weekly prevalence of infection-asso-
ciated parameters (macrohaematuria, microhaematuria,
proteinuria and leukocyturia) was calculated. When sum-
marising the results at weekly intervals, a child was con-
sidered as overall positive for a parameter if a positive
result was measured at any day of the weekly urine exam-
ination. Because samples were not tested with reagent
strips on the last day of the survey, data for reagent strip
testing and macroscopic examination is only available
until week 8 post-treatment.
Results
Study cohort
A total of 131 schoolchildren were registered on the class
lists of grades 3–6, provided by the teachers. As shown in
Figure 1, 124 (94.7%) children had written informed con-
sent, and hence, were eligible for the baseline cross-
sectional survey. There were 62 girls (50.0%) and 62 boys.
The mean age was 11 years with a range from 7 to
15 years.
S. haematobium infections were detected in 98 of the 124
children examined (79.0%), with equal prevalences among
boys and girls. Heavy infection intensities were found in 34
of the infected children (34.7%), the remaining 64 infected
children (65.3%) had light infections.
On the first treatment day, 27 children (group 1) were
administered a single oral dose of praziquantel. Five days
later, another 63 children (group 2) were treated. EightS. haematobium-infected children were absent on both
treatment days, and hence excluded from the follow-up
surveys. These children received praziquantel at the end
of the study. Demographic characteristics and baseline
morbidity of our study cohort, stratified by the two
treatment groups, are presented in Table 1.
Dynamics of S. haematobium egg output after
praziquantel administration
In both groups the number of children with S. haemato-
bium eggs in urine decreased after treatment with prazi-
quantel. Figure 2a shows the prevalence of S. haematobium
infection on each sampling day and is summarised in
weekly intervals. The infection rate of 100% at baseline
started to slowly decrease in week 1 post-treatment
(93.3%), dropped considerably in weeks 2 (71.3%) and 3
(27.1%) and decreased further until week 6 (7.1%), followed
by a slight increase in weeks 7 (8.6%), and 8 (12.8%). The
lowest prevalence was observed in week 9 post-treatment
(5.0%).
The decreasing slopes of daily and weekly group AM and
GM egg count values from baseline to all follow-up days
are presented as dots in Figures 2b and 2c, respectively. In
both treatment groups, daily AM egg counts decreased
considerably within the first two days post-treatment, from
56.8 and 96.8 eggs/10 ml of urine, respectively, to 7.8 and
39.0 eggs/10 ml of urine, respectively. However, until
around day 7 post-treatment, AM egg counts increased
again, to a maximum level of 37.9 and 83.2 eggs/10 ml of
urine, respectively. Subsequently, AM egg counts dropped
Table 1 Baseline characteristics of the 90 S. haematobium-infected children included in the 62-day follow-up survey
after treatment with a single dose of praziquantel (40 mg/kg)
Characteristics Group 1 Group 2 Total
No. of children 27 63 90
Sex
Female n (%) 12 (44.4) 32 (50.8) 44 (48.9)
Male n (%) 15 (55.6) 31 (49.2) 46 (51.1)
Age (years)
Median 11 11 11
Mean 11.3 10.9 11.2
Range 7–15 8–15 7–15
S. haematobium infection status at baseline
Light infection n
(<50 eggs/10 ml of urine)
21 (77.8) 36 (57.1) 57 (63.3)
Heavy infection n
(≥50 eggs/10 ml of urine)
6 (22.2) 27 (42.9) 33 (36.7)
Mean S. haematobium egg counts (eggs/10 ml of urine)
AM egg count (95% CI) 57 (16–98) 97 (66–128) 85 (60–110)
GM egg count (95% CI) 11 (5–24) 41 (28–60) 28 (20–40)
AM, arithmetic mean; CI, confidence interval; GM, geometric mean.
The study was carried out in the village of Grand Moutcho in south Côte d’Ivoire between March and June 2010. Children are stratified by treatment group.
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urine, respectively) around day 11 post-treatment. The pat-
tern of GM egg count dynamics followed that of AM egg
counts. From day 13 post-treatment onwards until the end
of our observation period, the daily AM and GM egg
counts remained very low, reaching ERRs between 95.9%
and 100% on all sampling days in both groups.
The overall weekly AM egg count, shown as bars in
Figures 2b and 2c, dropped from 84.8 eggs/10 ml of urine
at baseline to 40.5 eggs/10 ml of urine in week 1 and 7.3
eggs/10 ml of urine in week 2 post-treatment, and contin-
ued to decrease to 1.7, 1.9 and 0.7 eggs/10 ml of urine in
weeks 3, 4 and 5 post-treatment, respectively. In weeks 6
and 7, a minimum of 0.3 eggs/10 ml of urine was observed.
A slight increase of the weekly counts to 0.8 and 1.3
eggs/10 ml of urine was observed in the last two weeks of
the survey. The weekly overall GM decreased parallel to
the AM until week 6 and remained constant at 0.1 eggs/
10 ml of urine until the end of our observation period.
Dynamics of infection-related parameters post-treatment
As shown in Figure 2d, the overall weekly prevalence of the
four infection-related parameters (i.e. macrohaematuria,
microhaematuria, proteinuria and leukocyturia) decreased
over the course of the treatment intervention. At the base-
line cross-sectional survey, 13 of the 90 S. haematobium-
infected children had visible blood in their urine, hence, a
prevalence of 14.4%. The number did not change over the
first week post-treatment, but decreased to 3 (3.5%) in week
2 post-treatment. Between weeks 3 and 6 post-treatment,no child presented with macrohaematuria, with the excep-
tion of one child with visible blood in urine at week 4. After
week 6 post-treatment, blood was observed in the urine of
four children. Among them was one girl (13 years) with
light infection intensity and one boy (13 years) with heavy
infection intensity that remained until the end of the sur-
vey. One girl (15 years) and one boy (11 years) had visible
blood in urine without passing eggs.
The prevalence of microhaematuria was also stable from
baseline to week 1 post-treatment (87.8%), but then
dropped sharply to 47.1% in week 2 post-treatment and
32.9% in week 3. Microhaematuria remained at around
30% until week 6 post-treatment. Towards the end of the
study, microhaematuria further decreased to a minimum of
16.3%, eight weeks after treatment.
The prevalence of proteinuria and leukocyturia among all
treated children increased from 70.0% and 38.9% at baseline
to 73.3% and 71.1%, respectively, in week 1 post-treatment.
Subsequently, both parameters decreased gradually until
week 5 post-treatment (3.6% and 2.4%, respectively). The
prevalence of proteinuria then increased to 11.6% in week 8
post-treatment, while the prevalence of leukocyturia
reached a minimum of 1.2% in week 7 post-treatment, then
increased to 9.3% in week 9 post-treatment.
Discussion
Praziquantel is the main pillar of schistosomiasis control.
The number of countries administering praziquantel within
the frame of preventive chemotherapy programmes to
school-aged children and other at-risk populations is
Figure 2 Dynamics of S. haematobium egg output and
associated infection parameters in two groups of children in
southern Côte d’Ivoire after a single oral dose of praziquantel
(40 mg/kg). Results of urine filtration, reagent strip testing and
visual examination of urine samples during the 62-day follow-up
period, among 90 school-aged children with a parasitologically
confirmed S. haematobium infection: (a) Frequency (%) of children
with S. haematobium eggs in urine; (b) arithmetic mean (AM) egg
counts per 10 ml of urine; (c) geometric mean (GM) egg counts per
10 ml of urine. Results are shown for each sampling day (dots) and
summarised in weekly intervals (bars). (d) Weekly results of reagent
strip testing and visual examination. Children were considered
positive for a specific parameter during each follow-up week if they
had at least one positive test result on one sampling day during the
respective 7-day period.
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schistosomiasis is currently available [15,21,24], there is a
need to closely monitor the efficacy of praziquantel, par-
ticularly in areas where high coverage is reached and treat-
ment is repeated frequently. Standard protocols for drug
efficacy assessment and monitoring do not yet exist, but are
needed, so that the potential development of drug resist-
ance can be detected early on [26,29]. For recommendation
of the most appropriate time point to assess CR and ERR
of praziquantel against S. haematobium infection, we stud-
ied the dynamics of S. haematobium egg output and asso-
ciated infection parameters over a 62-day period following
treatment with a standard dose of 40 mg/kg praziquantel in
a group of school-aged children in south Côte d’Ivoire.S. haematobium infection prevalence and egg output
post-treatment
We found that both CR and ERR were highly dependent
on the time of measurement post-treatment. The CR was
highest in week 6 (between day 36 and day 42) post-
treatment (92.9%). The AM and GM ERR increased sharply
in the first two weeks after treatment and showed a
constantly high level from week 3 post-treatment onwards
(>97.5%). These findings are in line with observations from
Gabon, where a significant reduction in daily S. haemato-
bium egg counts between day 3 and day 9 post-treatment
was observed, among schoolchildren treated with prazi-
quantel and observed for 35 days post-treatment [33]. A
study from South Africa found a high GM ERR (95.3%),
but only a moderate CR (57.9%) three weeks post-
treatment [34]. In Cameroon, observed CRs at weeks 3
and 6 were 40-50% and 83%, respectively, after praziquan-
tel administration [35], corroborating our findings. Hence,
we recommend that CRs be assessed at around day 36
post-treatment, whereas ERRs can be assessed considerably
earlier, from day 15 post-treatment onwards. However, it
should be noted that our results were obtained in a high
prevalence setting without prior praziquantel treatment,
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other areas with different infection intensity profiles that
have been subjected to prior large-scale administration of
praziquantel.
The tendency of finding increased egg output and a
higher number of S. haematobium-positive children in
weeks 7 and 8 post-treatment is possibly due to schistoso-
mula that were not affected by praziquantel, and hence
have further developed, matured and paired up in the
weeks after treatment to start oviposition [29]. Reinfection
might have also occurred, but it is unlikely that one finds
S. haematobium eggs in the urine of newly infected indivi-
duals, as it takes more than 60 days from infection to ovi-
position [36]. Since our study started during the dry season
in March 2010, when the transmission of S. haematobium
should be low, the effect of juvenile worms might not be as
strong as during high transmission season [37]. An increase
in S. mansoni egg excretion already four weeks post-
treatment was observed in a preceding study conducted in
western Côte d’Ivoire that followed a similar design as the
work presented here [38]. Since the development of S. hae-
matobium worms takes considerably longer than that of
S. mansoni, whilst the period of insusceptibility is the same
in both species, egg output might be seen at a later stage
for S. haematobium than for S. mansoni [22,23,39]. How-
ever, it has been suggested that insusceptibility of schistoso-
mula to praziquantel is less pronounced in S. haematobium
than in S. mansoni [23]. A study from Cameroon did not
find lower CRs 9 weeks post-treatment compared to
6 weeks post-treatment and therefore suggested good effi-
cacy of praziquantel against all stages of S. haematobium
[35]. In view of our findings and those of others, we suggest
that CR should be assessed before week 7 post-treatment,
and we encourage further research on drug susceptibility of
immature S. haematobium worms.
Notably, the slight decrease in prevalence observed in
week 9 of our study is likely due to the fact that only one
instead of two urine samples per child were collected. In-
deed, previous research carried out in Côte d’Ivoire, South
Africa and Zimbabwe has shown that the more intense the
sampling effort post-treatment, the lower the observed CR
[34,40-42]. Future standard operating procedures should
therefore include advice on the sampling strategy for drug
efficacy monitoring. We suggest the microscopic examin-
ation of at least two urine samples, collected between
10:00 and 14:00 over consecutive days, for determining
praziquantel efficacy in terms of CR.
It is important to note that S. haematobium and
S. mansoni often co-exist [43-45]. In such co-endemic
settings, mainly for operational and practical reasons, it
would be useful to have a single time point for assess-
ment of praziquantel treatment efficacy. According to
our data pertaining to S. haematobium and recommen-
dations made by Scherrer and colleagues for S. mansoni[38], the optimal time points for assessment of CRs dif-
fer between the two schistosome species (i.e. week 3
post-treatment for S. mansoni and week 6 post-treatment
for S. haematobium). As a compromise, perhaps, CRs of
both infections could be measured in weeks 4 or 5 post-
treatment. However, it needs to be considered that at this
time point, S. haematobium infection prevalence might not
be at a minimum, and hence care is indicated with regard
to drug efficacy evaluation and monitoring of potential re-
sistance development. If morbidity control rather than
elimination of schistosomiasis is the goal of the treatment
intervention, assessing ERRs in both species at one time
point will be a useful strategy. Indeed, egg counts of both
species have been shown to be constantly low in both spe-
cies from week 3 post-treatment onwards [38]. We con-
clude that ERRs can be assessed at a single time point
from day 14 post-treatment onwards.
S. haematobium egg output during the first days post-
treatment
The observation that S. haematobium egg counts first
dropped rapidly within one day but increased again until
the end of the first week post-treatment before they
dropped sharply and remained at low levels from week 3
onwards seems an artefact at first sight. However, this
phenomenon has also been described for S. mansoni egg
output after treatment with praziquantel [38]. One possible
explanation is that not all adult worms die immediately
after treatment but some might be paralysed and repro-
duce heavily before dying within weeks 1–3 post-treat-
ment. Another explanation might be that praziquantel has
a direct effect on the host tissue, leading to a decreased re-
lease of eggs into the bladder. Praziquantel might also have
a direct effect on S. haematobium eggs. Indeed, it has been
described that praziquantel in very high doses can lead to
hatching of eggs in the tissue [46]. If this finding is translat-
able to regular treatment doses with praziquantel, the
temporary “disappearance” of schistosome eggs might not
be due to dying adult worms but rather due to early hatch-
ing of miracidia. Further research is needed to elucidate the
exact mechanisms of praziquantel on eggs, different devel-
opmental stages of the worms and reactions in the human
body.
Other infection parameters post-treatment
In addition to studying egg output dynamics using
the urine filtration method, we assessed the evolution
of S. haematobium-associated infection parameters after
treatment with praziquantel. As shown in previous studies,
the prevalence of microhaematuria, proteinuria and leuko-
cyturia decreased after treatment with praziquantel
[47-50]. Proteinuria and leukocyturia showed a transient
minimum around week 5 post-treatment. Both parameters
increased again towards the end of our 2-month
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excreted by surviving worms and triggering inflammation
and lesions in the urinary tract. Microhaematuria remained
more common than the other parameters until the end of
the study and many children were still passing blood in
urine without excreting S. haematobium eggs. Towards the
end of our study, four children had macrohaematuria, but
they did not pass any or only very few eggs in their urine.
Possible explanations for the remaining macrohaematuria
are as follows. First, two of the children were girls, aged 13
and 15 years, and hence the observed blood might be due
to menstruation. Second, one 13-year-old boy had likely
high exposure levels, since he presented with a heavy infec-
tion before treatment and had a very quick increase in egg
counts shortly after treatment.
Our findings of lasting egg-negative haematuria after
treatment are in line with a study from Kenya where the
prevalence of microhaematuria decreased more slowly than
the prevalence of eggs detected by microscopy and where it
took 4 to 6 months until the lowest levels were reached
[51,52]. Lesions in the urinary tract with small bleeds might
still be present even after egg output has terminated. In-
deed, ultrasound examination has shown that urinary tract
pathology resolves at a slower rate than reduction in egg
output during the first months after treatment [52,53]. As
for microhaematuria, a decrease of proteinuria and leuko-
cyturia 5 to 6 weeks post-treatment might serve as an add-
itional parameter for drug efficacy and morbidity reduction
assessment in settings of high endemicity where initial pre-
valences of microhaematuria, proteinuria and leukocyturia
are elevated [18,54].Conclusion
Praziquantel was highly efficacious against S. haematobium
among school-aged children in an area with high endem-
icity in south Côte d’Ivoire where no prior treatment cam-
paigns took place. Prevalence and intensity of infection,
haematuria, proteinuria and leukocyturia all decreased
sharply. Praziquantel efficacy against urogenital schisto-
somiasis in terms of ERR should be measured at the earli-
est from week 3 post-treatment. The optimal time point
for CR assessment in our study was at week 6 post-treat-
ment. In settings where S. haematobium and S. mansoni
co-exist, drug efficacy evaluation at a single time point,
perhaps at weeks 4 to 5 post-treatment, should be envi-
saged. For an accurate assessment of the CR, multiple
urine samples collected over consecutive days are needed.
Reagent strip testing, indicating a decrease of microhae-
maturia, proteinuria and leukocyturia after treatment
might serve as a valuable tool for the evaluation of treat-
ment success. We encourage other researchers to study
further the exact mechanisms of praziquantel on all stages
of S. haematobium in the human body, in order to explainthe phenomenon of a transitory drop of egg counts during
the first days after treatment.
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